Treatment of cutaneous squamous cell carcinoma (cSCC) primarily consists of surgical removal. The intralesional application of 5-fluorouracil might be a non-surgical alternative for select cases of cSCC, although currently no trial data exists.
Dr Emma Guttman-Yassky (Mount Sinai School of Medicine, USA) presented data from a reported retrospective single-centre analysis of 37 adults, which included a total of 195 cSCC tumours. The authors evaluated the efficacy of 5-fluorouracil in cSCC, including other patient and tumour characteristics, such as lesion, sex, and immunosuppression status .
Patients had a mean age of 70.5 years. The overall clearance rate was 87.2% (response in 170 tumours). Lesions of the extremities had a better percentage of clearance (arms 91%, legs 92%) than tumours on the face and neck (59%). Odds of treatment failure were higher in bigger tumours. Immunosuppressed patients had lower clearance rates (76%) compared with immu...
Please login to read the full text of the article.
If you have no account yet, please register now.
« Serlopitant reduces pruritus associated with psoriasis Next Article
Bruton’s tyrosine kinase inhibitor highly effective in pemphigus vulgaris »